A panel of investigators, including Beena Akolkar, PhD, will present recent findings from the ongoing TEDDY Study during the Scientific Sessions. TEDDY is a multi-center study funded by the NIDDK designed to investigate the etiology of type 1 diabetes and identify environmental triggers of the disease.
Guoxun Chen, PhD, previews his response and discussion from the Professional Interest Group Discussion “Nutritional Science and Metabolism—Emerging Methodologies for Personalized Nutrition—Potential Effects on Glycemic and Other Diabetes-Related Outcomes?” The session begins at 11:30 a.m. CT Saturday, June 13. Dr. Chen’s presentation will begin at 12:10 p.m. CT.
Emma E. Hamilton-Williams, PhD, describes results from the TOGeTHER Trial of type 1 diabetes patients, who were treated with a specially modified dietary fiber designed to deliver short-chain fatty acids into the large intestine. Her presentation details the impact of the supplement on the gut bacteria and diabetes management of the participants, revealing a promising…
Shivani Agarwal, MD, MPH, Shakira Suglia, ScD, MS, and J. Frank Wharam, MD, MPH, will examine strategies to address risks influenced by social needs and to improve outcomes.
Kristen J. Nadeau, MD, MS, outlined the unique cardiometabolic mechanisms and consequences of youth-onset type 1 and type 2 diabetes in her award lecture.
Samuel Klein, MD, and Blandine Laferrère, MD, PhD, presented different viewpoints on whether the metabolic benefits of Roux-en-Y gastric bypass surgery are due to weight loss alone.
Little is known about the impact of low-calorie sweeteners on taste preferences, insulin secretion, adipogenesis, the gut microbiome, glucose absorption, and the risk of cardiometabolic disease, according to Michelle Pang, BSc. One reason for that is that they are structured differently but are often studied together, resulting in conflicting findings.
CGM technology has the potential for use as a preventative tool in diabetes and obesity, and researchers continue to learn more about the effects of CGM use in people living with diabetes who are treated with insulin and those who are not. Three experts, including Ronnie Aronson, MD, will discuss emerging evidence.
Pathway to Stop Diabetes® researchers, including Aleksandar D. Kostic, PhD, presented their new approaches for working toward a cure for this pervasive disease. These investigators are looking at the gut microbiome, cloaked beta-cells, branched-chain amino acid, dysregulation of the gut-brain axis by sugar, and diabetes distress with new perspectives with funding from the American Diabetes…
Therapeutic inertia is a common problem in managing type 2 diabetes. Experts including Kevin M. Pantalone, DO, ECNU, FACE, addressed how it can be prevented, such as achieving A1C targets within a year of treatment, leveraging the entire health care team in the patient’s journey, and having accessibility to the patient’s electronic health record.